First, it will be necessary to demonstrate that a sufficiently high proportion of primary CD4+ T cells, the target of HIV-1 infection, can be engineered to express A3G-D128K to effectively inhibit HIV-1 replication and spread. This evidence concerns the gene CD4 and HIV-1 infection.